New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
05:55 EDTPFE, PFE, PFE, JNJ, JNJ, JNJ, SNY, SNY, SNY, AMGN, AMGN, AMGN, OREX, OREX, OREX, SGEN, SGEN, SGEN, SHPG, SHPG, SHPG, AGN, AGN, AGN, MRK, MRK, MRK, INFI, INFI, INFI, VPHM, VPHM, VPHM, NVO, NVO, NVOCambridge Healthtech Institute to host a summit
4th Annual Summit for Clinical Ops Executives: SCOPE to be held in Miami on February 5-7.
News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
January 12, 2015
08:47 EDTSHPGShire acquisition favorable, says RBC Capital
Subscribe for More Information
08:37 EDTMRK, JNJ, SNY, SHPG, PFEShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTSGENSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:14 EDTINFIInfinity Pharmaceuticals sees reporting Dynamo data in 2H15
Infinity (INFI) anticipates that it will report top line data from DYNAMO, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma, in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUO, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia, in the second half of 2015. During the year, Infinity expects three company-sponsored clinical studies of duvelisib to be initiated, including the first clinical study of duvelisib in combination with venetoclax . Duvelisib is an investigational oral inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma being developed jointly with AbbVie (ABBV) in oncology.
08:14 EDTSHPGShire acquisition positive, says SunTrust
Subscribe for More Information
08:13 EDTINFIInfinity Pharmaceuticals sees FY15 revenue $105M-$125M, consensus $96.45M
Subscribe for More Information
08:09 EDTAGNActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTAGNActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
08:00 EDTSHPGShire deal for NPS Pharmaceuticals positive, says Susquehanna
Subscribe for More Information
07:56 EDTSHPGShire price target raised to $257 from $223 at William Blair
Subscribe for More Information
07:21 EDTJNJ, MRKEBD Group to hold a conference
Subscribe for More Information
07:17 EDTAMGNJPMorgan to hold a conference
Subscribe for More Information
07:11 EDTSHPGNPS Pharmaceuticals volatility elevated into being acquired by Shire in a $5.2B
Subscribe for More Information
07:07 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:05 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
07:04 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:03 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
06:53 EDTMRKMerck to speed up plans for drug submission, WSJ says
Merck is speeding up its plans to submit new drugs for lung cancer and hepatitis C for regulatory approval, reports the Wall Street Journal. The company will file an application with the FDA around the mid-2015 to expand the use of Keytruda, the Journal adds. Reference Link
06:22 EDTMRKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
January 11, 2015
11:08 EDTSHPGShire acquires NPS Pharmaceuticals for $46 per share or $5.2B
Shire (SHPG) and NPS Pharmaceuticals (NPSP) announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2B. Shire said it "will accelerate the growth of NPS Pharma's innovative portfolio through its market expertise in gastrointestinal disorders, core capabilities in rare disease patient management, and global footprint." The transaction has been approved unanimously by the boards of both Shire and NPS Pharma. The $46 per share price in the transaction represents a 51% premium to NPS Pharma's unaffected share price of $30.47 on December 16, 2014. The acquisition is expected to enhance Shire's revenue and earnings growth profile. Shire expects the transaction to be accretive to non-GAAP earnings from 2016 onward. Related to the acquisition, Shire anticipates that it will realize operating synergies beginning in 2016 and growing "substantially" thereafter. Shire anticipates synergies approximating 25%-35% of the Street's consensus forecast of NPS Pharma's standalone future operating cost base from 2017 onward. Shire also expects that the transaction will deliver ROIC in excess of its weighted average cost of capital. Shire has secured an $850M fully underwritten short-term bank facility, which, in addition to Shire's cash and cash equivalents and its existing $2.1B five-year revolving credit facility, is available to finance the transaction and pay related fees and expenses. Shire plans to refinance the short-term bank facility through new debt issuances in "due course." The closing of the deal is anticipated in Q1 of 2015. Shares of NPS closed Friday down $1.01 to $41.91.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use